Skip to content
Screener

Tyra Biosciences, Inc. TYRA Personnel Costs — Research And Development Expense

Other segment segments

IRNMIBC
$5.25M+307%
ACH
$4.31M+20.1%
FGFR Discovery
$2.53M-19.2%
LGUTUC
$2.44M
Facilities And Other Costs
$1.63M+16.3%
MUC
$1.61M-50.4%
Other Development Programs
$849K+65.2%

Similar metrics at other companies

Dianthus Therapeutics logo
DNTHPersonnel And Related Costs — Research And Development Expense
$8.64M+47.7%
Tango Therapeutics logo
TNGXPersonnel-Related Expenses-RD — Research And Development Expense
$12.93M-6.6%
Rapport Therapeutics, Inc. logo
RAPPResearch And Development Personnel Related Costs Including Stock-Based Compensation — Research And Development Expense
$10.64M+59.6%
Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Ashland logo
ASHPersonal Care And Household — Research And Development Expense
$6M0.0%
Dianthus Therapeutics logo
DNTHOther Costs — Research And Development Expense
$1.49M+25.5%

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.61B+174%
Enterprise value$1.53B+210%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Reported directly by Tyra Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 8:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-220645
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
FGFR discovery2,5323,132
Other development programs849514
Unallocated research and development expenses:
Personnel costs(1)11,7888,023
Facilities and other costs(2)1,6341,405
Total research and development expenses33,47024,964
General and administrative expenses(3)8,5286,886
Interest and other income, net(2,693)(3,703)

Item 1. Condensed Financial Statements

FAQ

What is Tyra Biosciences, Inc.'s personnel costs — research and development expense?
Tyra Biosciences, Inc. (TYRA) reported personnel costs — research and development expense of $11.79M in Q1 2026.
How has Tyra Biosciences, Inc.'s personnel costs — research and development expense changed year-over-year?
Tyra Biosciences, Inc.'s personnel costs — research and development expense increased by 46.9% year-over-year, from $8.02M to $11.79M.
What is the long-term trend for Tyra Biosciences, Inc.'s personnel costs — research and development expense?
Over 2 years (2023 to 2025), Tyra Biosciences, Inc.'s personnel costs — research and development expense has grown at a 34.4% compound annual growth rate (CAGR), from $20.04M to $36.22M.
What does personnel costs — research and development expense mean?
This metric represents the total compensation and benefits-related expenditures allocated to personnel directly involved in research and development activities. It reflects the company's investment in human capital required to drive its drug discovery pipeline and clinical development programs. Tracking this expense provides insight into the organization's capacity to execute its scientific strategy and the scale of its internal innovation efforts.

Ask your AI about Tyra Biosciences, Inc.'s personnel costs — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude